The Bruton tyrosine kinase (BTK) inhibitor has shown promising results in improving hemodynamics, reducing right ventricular hypertrophy, and mitigating pulmonary arterial remodeling and fibrosis, as well as reversing endothelial-to-mesenchymal transition in PAH rats (109). Here, BTK is linked to pulmonary arterial hypertension.